Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Dow Inc (DOW) Price & Performance

Adaptive Biotechnologies CorpTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Dow Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Dow Inc trades at $31.2 (market cap $22.09B). The key difference: Dow Inc is far larger — about 5.5× Adaptive Biotechnologies Corp's market cap, and Dow Inc pays a 4.58% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTDOW
Market Cap
$4.05B$22.09B
Sector
HealthBasic Materials
52-Week High
$25.45$41.87
52-Week Low
$12.30$20.65
Enterprise Value
$4.12B$37.78B
Dividend Yield
4.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Dow Inc

DOW trades at $29.34, down 3.17% today, with technical indicators showing bearish momentum. The company faces fundamental challenges with negative net income margin of -3.13% and declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings beats provide some optimism, but cash flow from operations has weakened significantly from $7.5B in 2022 to $1.0B in 2025. The stock trades near the lower end of analyst price targets with consensus at $35.11.

DOW presents a mixed investment case with valuation metrics showing potential undervaluation (P/S 0.51) offset by profitability concerns. The chemical sector faces cyclical pressures, but recent dividend payments and earnings beats suggest operational resilience. Key risks include continued revenue decline and high debt levels approaching 30% of assets. Analyst sentiment remains cautious with only 33% buy ratings.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Dow Inc

Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.

Read more on DOW